|
A phase III study of trabectedin (T) plus pegylated liposomal doxorubicin (PLD) versus PLD for treatment of advanced-relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer. |
| |
|
|
Consulting or Advisory Role - Clovis Oncology; Esperance Pharmaceuticals; Genentech/Roche |
Research Funding - Amgen; Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Esperance Pharmaceuticals; Johnson & Johnson; Merrimack; OncoMed |
Travel, Accommodations, Expenses - Amgen; Array BioPharma; AstraZeneca/MedImmune; Gradalis; Merck; Merrimack; Millennium |
| |
|
No Relationships to Disclose |
| |
|
Employment - Johnson & Johnson; Johnson & Johnson (I) |
Stock and Other Ownership Interests - Johnson & Johnson; Johnson & Johnson (I) |
Patents, Royalties, Other Intellectual Property - University of Pennsylvania |
Travel, Accommodations, Expenses - Johnson & Johnson; Johnson & Johnson (I) |
| |
|
Employment - Johnson & Johnson |
Leadership - Johnson & Johnson |
Stock and Other Ownership Interests - Johnson & Johnson |
Travel, Accommodations, Expenses - Johnson & Johnson; Lilly (I) |
| |
|
Employment - Janssen Research & Development; Parexel |
Travel, Accommodations, Expenses - Janssen Research & Development; Parexel |
| |
|
Employment - Janssen Research & Development |
| |
|
Employment - Johnson & Johnson |
Stock and Other Ownership Interests - Johnson & Johnson |
Travel, Accommodations, Expenses - Johnson & Johnson |
| |
|
No Relationships to Disclose |